Literature DB >> 10699268

Drug solubilization in lung surfactant.

T S Wiedmann1, R Bhatia, L W Wattenberg.   

Abstract

The relative affinity of glucocorticosteroids for lung surfactant was determined for the purpose of identifying chemopreventive agents with a high therapeutic index for lung cancer. The aqueous solubility and the extent of solubilization in Survanta, a native extract of bovine lung, of budesonide, triamcinolone acetonide, dexamethasone, and flunisolide were determined as a function of temperature by a dialysis technique. The aqueous solubilites at 37 degrees C were 19.6, 35.8, 104 and 120 microg/ml for the above listed compounds, respectively. The temperature dependence of the solubilities was modest consistent with the hydrophobic properties of the steroids. The amount of drug in solution was significantly enhanced in the presence of Survanta with solubilization ratios of 0. 019, 0.023, 0.014, and 0.02 microg drug dissolved per microg of Survanta phospholipid, respectively. In addition, the extent of solubilization also generally increased with temperature, although the phase transition of the surfactant lipid appeared to complicate the functional relation between temperature and solubilization. These results show that there is enhanced solubilization of glucocortosteroids by lung surfactant which is secreted by the cancer susceptible type II cells of the lung.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699268     DOI: 10.1016/s0168-3659(99)00230-8

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  13 in total

1.  Ocular pharmacokinetic study of a corticosteroid by 19F MR.

Authors:  Xin Liu; S Kevin Li; Eun-Kee Jeong
Journal:  Exp Eye Res       Date:  2010-06-09       Impact factor: 3.467

2.  Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model.

Authors:  Paul J Missel; Marc Horner; R Muralikrishnan
Journal:  Pharm Res       Date:  2010-05-14       Impact factor: 4.200

3.  Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant a a carrier.

Authors:  Yi E Wang; Hong Zhang; Qihui Fan; Charles R Neal; Yi Y Zuo
Journal:  Soft Matter       Date:  2011-11-01       Impact factor: 3.679

4.  Small Airway Absorption and Microdosimetry of Inhaled Corticosteroid Particles after Deposition.

Authors:  P Worth Longest; Michael Hindle
Journal:  Pharm Res       Date:  2017-06-22       Impact factor: 4.200

5.  A systematic review and meta-analysis of pulmonary surfactant combined with budesonide in the treatment of neonatal respiratory distress syndrome.

Authors:  Zongyan Yi; Yajuan Tan; Yang Liu; Ling Jiang; Li Luo; Liang Wang; Wei Lei; Jiping Tan; Ruofen Yan
Journal:  Transl Pediatr       Date:  2022-04

6.  Solubilization of cationic drugs in lung surfactant.

Authors:  Xiangmin Liao; Timothy S Wiedmann
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

7.  Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins.

Authors:  Laura J Peek; Lydia Roberts; Cory Berkland
Journal:  Langmuir       Date:  2008-08-05       Impact factor: 3.882

8.  Development and validation of a physiology-based model for the prediction of oral absorption in monkeys.

Authors:  Stefan Willmann; Andrea N Edginton; Jennifer B Dressman
Journal:  Pharm Res       Date:  2007-03-21       Impact factor: 4.580

9.  Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model.

Authors:  Matthias Freiwald; Anagnostis Valotis; Andreas Kirschbaum; Monika McClellan; Thomas Mürdter; Peter Fritz; Godehard Friedel; Michael Thomas; Petra Högger
Journal:  Respir Res       Date:  2005-02-24

Review 10.  Inhaled nano- and microparticles for drug delivery.

Authors:  Ibrahim M El-Sherbiny; Nancy M El-Baz; Magdi H Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2015-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.